RT Journal Article
SR Electronic
T1 Measles Virus Genotype A in Canada’s Capital Region Wastewater Associated with Public Health Vaccination Initiatives
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.11.24315327
DO 10.1101/2024.10.11.24315327
A1 Tomalty, Emma
A1 Mercier, Élisabeth
A1 Pisharody, Lakshmi
A1 Nguyen, Tram
A1 Tian, Xin
A1 Kabir, Md Pervez
A1 Wong, Chandler
A1 Addo, Felix
A1 Hegazy, Nada
A1 Renouf, Elizabeth
A1 Wan, Shen
A1 Delatolla, Robert
YR 2024
UL http://medrxiv.org/content/early/2024/10/18/2024.10.11.24315327.abstract
AB The recent global resurgence of measles in 2023-2024, despite its preventability through vaccination, is a significant public health concern largely driven by decreased vaccination coverage during the SARS-CoV-2 pandemic. To address this resurgence and to restore vaccine coverage disrupted by the pandemic, Ottawa Public Health intensified vaccination efforts in 2023 and 2024. Additionally, a research initiative began in April 2024 to monitor Ottawa wastewater for measles virus (MeV) using established wastewater and environmental surveillance (WES) protocols. Given the absence of active measles cases in the Ottawa region, unexpected positive MeV detections through RT-qPCR prompted genotypic analysis as well as retrospective analysis of archived RNA samples dating back to 2020. The genotypic analysis identified positive detection to belong to genotype A, the progenitor strain of the viral vaccines, marking the first report of MeV RNA and MeV vaccine shedding in North American wastewater. Positive detections in both real-time and retrospectively analysed samples coincided with the increased vaccination efforts by Ottawa Public Health. These finding emphasize the importance of integrating genotypic analysis into WES practices to mitigate possible confounding factors, such as vaccine shedding into wastewater. Additionally, this research highlights the potential application of MeV WES for monitoring community immunization efforts in real time. Implementing the findings of this study for MeV WES, as well as for other re-emerging viruses, will enhance the accuracy of public health response and optimize resource allocation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the CIHR Applied Public Health Research Chair in Environment, Climate Change and One Health, awarded to Dr. Robert Delatolla. The funding source had no involvement in the study design, data collection, data analysis, data interpretation, nor the writing or decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors